Table 1.
Epigenetics alterations in hematological malignancies.
| Disease | Status | Target | Type of Study | Ref. |
|---|---|---|---|---|
| AML | Hypomethylation | MAGE-1 | In vitro | [122,123] |
| AML (HLA60 cell line) | Hypermethylation | H3K4mc3 | In vitro | [138] |
| ALL (TK6 cells lymphoblastoid cells) | Hypomethylation | DNA | In vitro | [140] |
| ALL (Children) | Hypermethylation | MLL-r | Ex vivo | [132] |
| Experimental model | Target | Type of study | Ref. | |
| Male C76B/6 mice | Leukemia stem cell quiescence and self renewal genes | In vivo | [135] | |
| Exposed subjects | Hypomethylation | p15, MAGE-1, Line-1 | Ex vivo | [136] |
| Exposed subjects | Hypomethylation | P15INK4b | Ex vivo | [157] |
| Exposed subjects | JUN, PF4, CXCL16, ZNF331 | Ex vivo | [158] | |
| Exposed subjects | Hypomethylation Hypomethylation |
PRKG1, PARD3, EPHAS. STAT3, IFNGR1 |
Ex vivo | [162] |
| Exposed subjects | Hypermethylation | p15, p16 | Ex vivo | [163] |
| Bone marrow rat cells, F32 lymphoblast cells | Hypermethylation | PTEN | In vitro and in vivo | [166] |